When we first met Yesli Jordán Paillacán, she was a shy young girl living in Araucanía, Chile’s poorest region in terms of gross domestic product per capita where 80 percent of the population depends on the public health system. Yesli’s life had been continually disrupted by frequent hospitalizations that typically lasted from five to 10 days, and by other health complications that dramatically affected her quality of life.
Access to care in rural areas
She could not attend school regularly, particularly in the winter, when weather conditions exacerbated her condition. Access to care for patients like Yesli in rural areas of Chile is complicated by the distances that often separate them from hospitals and health care centers. In rural areas patients must often travel over rugged mountainous terrain to receive medical treatment.
That’s why awareness opportunities such as HAE Day are so important.
By Debra Bensen-Kennedy, MD
May 15, 2017
Like many physicians, I learned about hereditary angioedema (HAE) during a brief moment in my years of education and training. Had I not worked at CSL Behring, HAE would likely never cross my mind again, given its rarity.
Medical professionals juggle troves of clinical information, and on HAE Day we help keep the disease top of mind. Because HAE attacks can be life-threatening if they occur in the throat, it is extremely important for healthcare professionals to know what to do when they encounter a patient, even if their only other experience with the condition was during their medical training.
Antibiotic resistance and rare diseases were among the topics explored by a panel of scientists and pharmaceutical industry representatives in Marburg, Germany.
By Dr. Lutz Bonacker
May 8, 2017
Philipps University of Marburg, Germany, where members of the scientific and pharmaceutical communities examined a range of timely topics.
Earlier this year I joined distinguished members of the scientific and pharmaceutical communities for an academic panel hosted by Philipps University of Marburg, Germany, where CSL Behring operates a manufacturing and R&D facility for recombinant and plasma-derived coagulation factors, C-1 inhibitor and critical care products.
More patients are being properly diagnosed and treated than ever before, but obstacles remain in the pursuit of a cure.
By John Sleasman, MD
April 27, 2017
Immunologists are using innovative treatments such as cell-based therapies at Duke Children’s Hospital and Health Center (pictured above), which involves replacing missing cells or genes to correct primary immune deficiency diseases.
Photo courtesy of Duke Health
This is an exciting time in the Department of Pediatrics at Duke School of Medicine’s Division of Allergy and Immunology. Late last year we opened the Jeffrey Modell Center (JMF) for research and clinical care for children with primary immunodeficiency (PI) diseases — a group of more than 300 rare, chronic disorders in which part of the body’s immune system is missing or functions improperly.
High school student and common variable immune deficiency (CVID) patient, Baylee Gregory, is an avid golfer and soccer player who hopes to one day play those sports in college. That didn’t seem possible years ago when a doctor commented, “It’s a miracle you’re still alive.”
Now that she’s been diagnosed and is treating her primary immunodeficiency, her mom, Annette, says, “She’s going to live a life that she wants to live and not let things stand in her way.” Baylee and her mom shared their story with BioBlog at the start of World PI Week 2017.
BAYLEE: I always had sinus infections. I always had ear problems, stomach issues. Family trips I would always be the one sick. I’d go to the doctor and they would just tell me that it was allergies or take an antibiotic, it’s another sinus infection, it’ll go away. Continue reading →
Posts represent the opinion of the author and do not necessarily reflect the views of CSL Behring. This site is not intended as a forum for discussing CSL Behring or other companies' products. Comments on this blog may be reviewed by CSL Behring and may be subject to removal if they are deemed to have inappropriate content.